ReviewKidney international2010
Recent progress in the treatment of vascular calcification.
Review in Kidney international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 74 citations in OpenAlex.
- Sclerostin in Vascular Calcification: Hypoxia-Driven Regulation and Therapeutic Modulation by Natural Products.Current atherosclerosis reports · 2026Review
- Vitamin K3 Analog Phthiocol Protects Against High Phosphate-Induced Vascular Calcification in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2025Article
- Revascularization of coronary chronic total occlusion in patients with end stage renal disease.Scientific reports · 2025Article
- Article
- Vitamin K for Vascular Calcification in Kidney Patients: Still Alive and Kicking, but Still a Lot to Learn.Nutrients · 2024Review
- Comparison of cardiovascular event predictability between the 2009 and 2021 Chronic Kidney Disease Epidemiology Collaboration equations in a Korean chronic kidney disease cohort: the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease.Kidney research and clinical practice · 2023Article
- Vascular calcification: from the perspective of crosstalk.Molecular biomedicine · 2023Review
- A long non-coding RNA H19/microRNA-138/TLR3 network is involved in high phosphorus-mediated vascular calcification and chronic kidney disease.Cell cycle (Georgetown, Tex.) · 2022Article
- Framingham and American College of Cardiology/American Heart Association Pooled Cohort Equations, High-Sensitivity Troponin T, and N-Terminal Pro-Brain-Type Natriuretic Peptide for Predicting Atherosclerotic Cardiovascular Events Across the Spectrum of Kidney Dysfunction.Journal of the American Heart Association · 2022Article
- Magnesium to prevent kidney disease-associated vascular calcification: crystal clear?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Article
- Vitamin K Supplementation for Prevention of Vascular Calcification in Chronic Kidney Disease Patients: Are We There Yet?Nutrients · 2022Review
- Medial Arterial Calcification: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- Monckeberg's Medial Sclerosis as a Cause for Headache and Facial Pain.Current pain and headache reports · 2021Review
- Spermidine inhibits vascular calcification in chronic kidney disease through modulation of SIRT1 signaling pathway.Aging cell · 2021Article
- Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management.Calcified tissue international · 2021Review
- Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.Circulation · 2021Article
- Overlapping Genetic Background of Coronary Artery and Carotid/Femoral Atherosclerotic Calcification.Medicina (Kaunas, Lithuania) · 2021Article
- Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.British journal of pharmacology · 2020Article
- Site-specific chelation therapy with EDTA-loaded albumin nanoparticles reverses arterial calcification in a rat model of chronic kidney disease.Scientific reports · 2019Article
- Cell Sources for Tissue Engineering Strategies to Treat Calcific Valve Disease.Frontiers in cardiovascular medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vascular calcification is common in patients with advanced chronic kidney disease and is associated with poorer outcomes. Although the pathophysiology is not completely understood, it is clear that it is a multifactorial process involving altered mineral metabolism, as well as changes in systemic and local factors that can promote or inhibit vascular calcification, and all of these are potential therapeutic targets. Current therapy is closely linked to strategies for preventing disordered bone and mineral metabolism in advanced kidney disease and involves lowering the circulating levels of both phosphate and calcium. The efficacy of compounds that specifically target calcification, such as bisphosphonates and thiosulfate, has been shown in animals but only in small numbers of humans, and safety remains an issue. Additional therapies, such as pyrophosphate, vitamin K, and lowering of pH, are supported by animal studies, but are yet to be investigated clinically. As the mineral composition of vascular calcifications is the same as in bone, potential effects on bone must be addressed with any therapy for vascular calcification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.